A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma
- PMID: 26813914
- DOI: 10.1097/SLA.0000000000001556
A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma
Abstract
Objective: To review the current management, outline recent advances and address controversies in the management of hepatocellular carcinoma (HCC).
Summary of background data: The treatment of HCC is multidisciplinary involving hepatologists, surgeons, medical oncologists, radiation oncologists, radiologists, interventional radiologists, and other disciplines. Each of these disciplines brings its unique perspective and differing opinions that add to controversies in the management of HCC.
Methods: A focused literature review was performed to identify recent studies on the management of HCC and thereby summarize relevant information on the various therapeutic modalities and controversies involved in the treatment of HCC.
Results: The main treatment algorithms continue to rely on hepatic resection or transplantation with controversies involving patients harboring early stage disease and borderline hepatic function. The other treatment strategies include locoregional therapies, radiation, and systemic therapy used alone or in combination with other treatment modalities. Recent advances in locoregional therapies, radiation, and systemic therapies have provided better therapeutic options with curative intent potential for some locoregional therapies. Further refinements in combination therapies such as algorithms consisting of locoregional therapies and systemic or radiation therapies are likely to add additional options and improve survival.
Conclusions: The management of HCC has witnessed significant strides with advances in existing options and introduction of several new treatment modalities of various combinations. Further refinements in these treatment options combined with enrollment in clinical trials are essential to improve the management and outcomes of patients with HCC.
Comment in
-
We're Still in an Update Process of the BCLC System.Ann Surg. 2018 Feb;267(2):e23-e24. doi: 10.1097/SLA.0000000000001922. Ann Surg. 2018. PMID: 27455159 No abstract available.
-
Response to Letter: Hepatocellular Carcinoma: The Gap Between Eastern and Western Clinical Practice.Ann Surg. 2018 Feb;267(2):e28-e29. doi: 10.1097/SLA.0000000000001961. Ann Surg. 2018. PMID: 27537536 No abstract available.
-
Hepatocellular Carcinoma: The Gap Between Eastern and Western Clinical Practice.Ann Surg. 2018 Feb;267(2):e27-e28. doi: 10.1097/SLA.0000000000001960. Ann Surg. 2018. PMID: 27607096 No abstract available.
-
Response: "We Still in an Update Process of the BCLC System".Ann Surg. 2018 Feb;267(2):e24-e25. doi: 10.1097/SLA.0000000000002569. Ann Surg. 2018. PMID: 29064888 No abstract available.
Similar articles
-
Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.Ann Surg. 2002 Apr;235(4):466-86. doi: 10.1097/00000658-200204000-00004. Ann Surg. 2002. PMID: 11923602 Free PMC article. Review.
-
New treatment modalities for hepatocellular cancer.Curr Gastroenterol Rep. 2015 May;17(5):442. doi: 10.1007/s11894-015-0442-4. Curr Gastroenterol Rep. 2015. PMID: 25869473 Review.
-
Staging and current treatment of hepatocellular carcinoma.Radiographics. 2005 Oct;25 Suppl 1:S3-23. doi: 10.1148/rg.25si055507. Radiographics. 2005. PMID: 16227495 Review.
-
Curative-Intent Therapies in Localized Hepatocellular Carcinoma.Curr Treat Options Oncol. 2020 Mar 19;21(4):31. doi: 10.1007/s11864-020-0725-3. Curr Treat Options Oncol. 2020. PMID: 32193784 Review.
-
Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective.Eur J Gastroenterol Hepatol. 2013 Jun;25(6):639-51. doi: 10.1097/MEG.0b013e32835e33bb. Eur J Gastroenterol Hepatol. 2013. PMID: 23628963 Review.
Cited by
-
Long non-coding RNA SNHG7 inhibits NLRP3-dependent pyroptosis by targeting the miR-34a/SIRT1 axis in liver cancer.Oncol Lett. 2020 Jul;20(1):893-901. doi: 10.3892/ol.2020.11635. Epub 2020 May 18. Oncol Lett. 2020. PMID: 32566017 Free PMC article.
-
Cellular based treatment modalities for unresectable hepatocellular carcinoma.World J Clin Oncol. 2021 May 24;12(5):290-308. doi: 10.5306/wjco.v12.i5.290. World J Clin Oncol. 2021. PMID: 34131562 Free PMC article. Review.
-
Preoperative normalized iodine concentration derived from spectral CT is correlated with early recurrence of hepatocellular carcinoma after curative resection.Eur Radiol. 2021 Apr;31(4):1872-1882. doi: 10.1007/s00330-020-07330-6. Epub 2020 Oct 9. Eur Radiol. 2021. PMID: 33037444
-
The Performance of Serum Alpha-Fetoprotein for Detecting Early-Stage Hepatocellular Carcinoma Is Influenced by Antiviral Therapy and Serum Aspartate Aminotransferase: A Study in a Large Cohort of Hepatitis B Virus-Infected Patients.Viruses. 2022 Jul 29;14(8):1669. doi: 10.3390/v14081669. Viruses. 2022. PMID: 36016291 Free PMC article.
-
Surgical Margin Affects the Long-Term Prognosis of Patients With Hepatocellular Carcinoma Undergoing Radical Hepatectomy Followed by Adjuvant TACE.Oncologist. 2023 Aug 3;28(8):e633-e644. doi: 10.1093/oncolo/oyad088. Oncologist. 2023. PMID: 37029989 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials